12 results about "Phosphorylethanolamine" patented technology

The invention relates to a flame-retardant skin-friendly polyurethane sponge with in-situ reaction and bio-enzyme catalysis synergism. The water-based polyurethane foam is prepared from the following components: polyether polyol, diphenylmethane diisocyanate or toluene diisocynate, a chain extender, a high-efficiency foam stabilizer, a high-efficiency composite catalyst, water and ethanolamine phosphate, ethanolamine phosphate is added into water in advance, and then all the raw materials are mixed for polymerization foaming; after curing, spraying a spraying liquid consisting of phosphoethanolamine, regenerated protein and transglutaminase to generate a nano protein film, and synchronously performing vacuum suction to keep sponge pores unblocked. The preparation method has the advantages that a small amount of ethanolamine phosphate is added before polymerization foaming to serve as a phosphorus-nitrogen synergistic flame retardant and also serve as a catalytic cross-linking agent to participate in a reaction during polymerization, biological enzyme is added for catalysis after curing is finished, and the skin-friendly PU sponge with excellent flame retardance is prepared through in-situ polymerization reaction and biological enzyme enzymatic polymerization cooperation, and the sponge performance is not affected; the raw materials of the flame retardant come from biomass products and are environment-friendly and safe.

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.

The invention relates to an exosome with high permeability and application of the exosome, and the surface of the exosome is connected with dioleoyl phosphatidylserine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylethanolamine and hirudin. The exosome constructed by the invention can improve the permeability of the skin, can carry active components to directly reach the skin epidermis and corium layer, is accumulated on the epidermis and corium layer, continuously provides nutrition for the skin, and fully exerts the skin care and beautifying effects.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

The invention discloses a strain of Chryseobacterium wanjuense C14, and a preparation method of the Chryseobacterium wanjuense C14. The invention further discloses application of the bacillus subtilis in inhibition of ralstonia solanacearum and application of the bacillus subtilis in degradation of straw. The Chryseobacterium sp. C14 can obviously inhibit the growth of pathogenic bacteria of tomato bacterial wilt, especially under the assistance of tomato rhizosphere metabolites such as O-phosphoethanolamine, mangiferin and L-tryptophan, the antibacterial effect of the Chryseobacterium sp. C14 is further enhanced, and the Chryseobacterium sp. C14 has higher environmental adaptability and prevention and treatment potential. The Chryseobacterium sp. C14 can also degrade protein, cellulose and hemicellulose at the same time, and can significantly promote the degradation of rice straw and corn straw. The Chryseobacterium sp. C14 has the functions of straw degradation and tomato ralstonia solanacearum inhibition, integrates a soil-borne disease biological control function and efficient straw degradation, and provides a green and efficient microbial new strategy for solving the problems of difficult straw treatment and difficult tomato bacterial wilt control in agricultural production.

The invention relates to a sample pretreatment method for pyrite elemental analysis. The method comprises the following steps: firstly, preparing a pretreatment agent: activating the surface of carboxymethyl chitosan by NHS / EDC, and then reacting with ethanolamine phosphate; secondly, a pyrite sample is taken and smashed into particles, the particles, NaOH, NaNO3 and a pretreatment agent are fully ground into powder, then the temperature is increased to 180-250 DEG C and then increased to 350-450 DEG C for heat preservation, sintered solids are transferred into a beaker, a hot nitric acid solution is added, the solids are dissolved through ultrasonic treatment, the solids are filtered into a volumetric flask after being cooled, and a to-be-tested sample is obtained after the volume is fixed through dilute nitric acid; according to the treatment method, use of a large amount of concentrated acid and perchloric acid is avoided, the reagent dosage is small, and environment friendliness is achieved; the recovery rate of 95% or above can be ensured when the treated sample is measured by instruments such as ICP-MS, the maximum RSD value does not exceed 5% compared with a standard value, and the accuracy is good.

The application relates to a sample pretreatment method for pyrite element analysis. First, a pretreatment agent is prepared: carboxymethyl chitosan is activated on the surface through NHS / EDC, and then reacts with phosphoethanolamine to obtain the pretreatment agent; secondly, a pyrite sample is crushed into particles, and is fully ground into powder together with NaOH, NaNO3 and the pretreatment agent; then, the temperature is increased to 180-250 DEG C and then to 350-450 DEG C for heat preservation; the sintered solid is transferred into a beaker, hot nitric acid solution is added, ultrasonic is used to dissolve the solid, and after cooling, filtration is carried out into a volumetric flask, and dilute nitric acid is used for constant volume to obtain a sample to be tested. The treatment method avoids the use of a large amount of concentrated acid and perchloric acid, the reagent consumption is small, and the method is environment-friendly; the treated sample is determined by an ICP-MS instrument and the like, and the recovery rate can be ensured to be above 95%; compared with a standard value, the RSD value is not more than 5%, and the accuracy is good.

A use of gut microbiota or a metabolite thereof and / or an antibody or a derivative thereof in preparation of immunotherapeutic drugs for colorectal cancer. The gut microbiota comprises at least one of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Actinomyces humiferus, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The metabolite of the gut microbiota comprises at least one of O-phosphorylethanolamine, 5,6-dihydroxyindole-2-carboxylic acid, phosphatidylcholine (O-16:0_20:4), and 4-acetamidobutyric acid. The antibody comprises an IL-17A signaling pathway monoclonal antibody and / or a colorectal cancer-targeted monoclonal antibody.

The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and / or phosphoethanolamine transferase and / or glucans biosynthesis protein C to reduce oligosaccharide by-products and / or increase oligosaccharide production.

The present invention is directed to a method for detecting the presence or absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, comprising: (a) subjecting a test sample to mass spectrometry analysis and generating a mass spectrum output; wherein said test sample comprises a bacterial membrane or a fragment thereof, wherein the fragment comprises a non-Lipid A component; (b) identifying in said mass spectrum output a first defined peak indicative of the presence of Lipid A modified by phosphoethanolamine, wherein said first defined peak is a peak present in a mass spectrum output for Lipid A modified by phosphoethanolamine and wherein said first defined peak is absent from a corresponding mass spectrum output for native Lipid A; and (c) wherein the presence of said first defined peak indicates the presence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, and wherein the absence of said first defined peak indicates the absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic. This method is also used in a screening method to identify an inhibitor of cyclic cationic polypeptide antibiotic resistance in a bacterium. The matrix solution can contain 2,5-dihydroxybenzoic acid and aids in the selective extraction, co-crystallisation and ionisation of native Lipid A and / or modified Lipid A as an integral part of a bacterial membrane.

A lipid nanoparticle and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject. The lipid nanoparticle may contain 55-65 mol% of a cationic lipid to the total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 1-3 mol% of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle. The lipid nanoparticle may also contain 55-65 mol% of a cationic lipid to a total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 4-6 mol% of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle.

The invention relates to a nano preparation and a preparation method and application thereof, in particular to the technical field of biomedical materials. The nano preparation has a core-shell structure and comprises a core and a shell, the core comprises a photosensitizer and a glycometabolism inhibitor, the shell comprises an amphiphilic polymer, the photosensitizer is a near-infrared two-region fluorescent dye TTQ-BT-TPA, the glycometabolism inhibitor comprises lonidamine, the amphiphilic polymer comprises 1, 2, 4-trimethyl-1, 3-pentanediol monoisobutyrate, and the 1, 2, 4-trimethyl-1, 3-pentanediol monoisobutyrate is a near-infrared two-region fluorescent dye TTQ-BT-TPA. The composition is prepared from 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol 2000 and 2-distearoyl-sn-glycerol-3 The invention provides a nano preparation. In the prior art, a traditional photodynamic therapy is limited in curative effect in a tumor anoxic zone due to dependence on oxygen, and tumor cells maintain a high-level anti-oxidation defense system due to metabolism reprogramming and are insensitive to ferroptosis; and the problem of poor synergistic effect caused by lack of accurate intervention on tumor metabolism and reduction of the yield of fluorescence and active oxygen in a photosensitizer aggregation state of an existing synergistic treatment system is solved.